SMART IMM_LOGO NEW.png
Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial
02. Mai 2024 06:00 ET | Smart Immune
Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial PARIS, France, May 2, 2024 – Smart Immune, a clinical-stage biotechnology company developing...
SMART IMM_LOGO NEW.png
Smart Immune appoints key new members to its Board of Directors
16. Februar 2024 02:00 ET | Smart Immune
Smart Immune appoints key new members to its Board of Directors PARIS, France, 16 February 2024 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T cell...
SMART IMM_LOGO NEW.png
Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise
04. Dezember 2023 06:46 ET | Smart Immune
Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise PARIS, France, 04 December 2023 – Smart Immune, a clinical-stage...
SMART IMM_LOGO NEW.png
Smart Immune to host R&D KOL webinar on thymus-empowered ProTcell platform
10. November 2023 05:52 ET | Smart Immune
Smart Immune to host R&D KOL webinar on thymus-empowered ProTcell platform Clinical-stage T-cell progenitor therapy aims to re-arm the immune system against cancer and infection New class of...
SMART IMM_LOGO NEW.png
Smart Immune to Present Details of Pioneering Clinical Study at the American Society of Hematology (ASH) Annual Meeting 2023
02. November 2023 09:00 ET | Smart Immune
Smart Immune to Present Details of Pioneering Clinical Study at the American Society of Hematology (ASH) Annual Meeting 2023 PARIS, France, 02 November 2023 – Smart Immune, a clinical-stage...
CONS LOGO.png
First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy
23. Januar 2023 07:01 ET | Consilium Strategic Communications
First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy Phase I/II trial will assess safety and efficacy of SMART101 in accelerating immune reconstitution to...
Smart Immune pic
Smart Immune Bolsters Management Team with Medical and Technical Appointments
13. September 2022 07:00 ET | Smart Immune
Smart Immune Bolsters Management Team with Medical and Technical Appointments Dr Frederic Lehmann, MD, appointed Chief Medical Officer and Dr Pierre Heimendinger, PharmD, appointed Chief Technical...